HPV vaccine nearly eliminates cervical cancer deaths in vaccinated young women, landmark study finds
By
Sophie Hutchinson
Summary
A landmark study reveals that girls vaccinated against HPV at age 12-13 have close to zero risk of dying from cervical cancer before age 30. Since the vaccine was introduced in English schools in 2008, cervical cancer deaths have fallen sharply, with no deaths recorded in women aged 20-24 between 2020 and 2024. Researchers estimate around 200 lives have been saved in England so far, with projections suggesting over 400 lives could be saved per year by 2050. The study provides the first direct evidence of the vaccine's life-saving impact.
Source
Key quotes
· 3 pulledChildren vaccinated at age 12–13 against HPV have close to zero risk of dying from cervical cancer before the age of 30, landmark new research reveals.
Between 2020 and 2024, no cervical cancer deaths were recorded in women aged 20 to 24 - the first time that had happened.
Around 200 lives have been saved in England so far thanks to the vaccine.
You might also wanna read
HPV vaccine linked to zero cervical cancer deaths in young women in England for first time
New data from England shows zero cervical cancer deaths among women aged 20-24 between 2020 and 2024, marking the first time this has been r
Long-term HPV vaccine effectiveness study shows stable protection against targeted virus types in Danish women vaccinated as girls
This study examines the long-term effectiveness of HPV vaccination in Danish women who received the 4-valent HPV vaccine as girls in 2008. T
HPV Vaccine at 20: Proven Cancer Prevention Tool Faces Uptake Challenges
The article marks the 20th anniversary of the FDA's approval of the first HPV vaccine in 2006, highlighting its evolution from a quadrivalen
Denmark Eliminates Leading Cancer-Causing HPV Strains Following 2008 Vaccine Rollout
Denmark has successfully eliminated infections from the two most dangerous cancer-causing HPV strains (types 16 and 18) following the introd

Study Examines Association Between mRNA COVID-19 Vaccination and 4-Year All-Cause Mortality in French Adults Aged 18-59
This cohort study analyzes data from over 28 million French adults aged 18-59 to examine the association between mRNA COVID-19 vaccination a
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·4mo agoComments
Sign in to join the conversation.
No comments yet. Be the first.
